Modeling MR Imaging Enhancing-Lesion Volumes in Multiple Sclerosis: Application in Clinical Trials

References

1. 1.↵
   1. Filippi M

   . Enhanced magnetic resonance imaging in multiple sclerosis. Mult Scler 2000;6:320–26

   Abstract/FREE Full Text
2. 2.↵
   1. Di Rezze S,
   2. Gupta S,
   3. Durastanti V,
   4. et al

   . An exploratory study on interferon beta dose effect in reducing size of enhancing lesions in multiple sclerosis. Mult Scler 2007;13:343–47

   Abstract/FREE Full Text
3. 3.↵
   1. Gupta S,
   2. Solomon JM,
   3. Tasciyan TA,
   4. et al

   . Interferon-beta-1b effects on re-enhancing lesions in patients with multiple sclerosis. Mult Scler 2005;11:658–68

   Abstract/FREE Full Text
4. 4.↵
   1. Polman C,
   2. Barkhof F,
   3. Kappos L,
   4. et al.

   , the European Oral Interferon Beta-1a in Relapsing-Remitting MS Study Group. Oral interferon beta-1a in relapsing-remitting multiple sclerosis: a double-blind randomized study. Mult Scler 2003;9:342–48

   Abstract/FREE Full Text
5. 5.↵
   1. Kappos L,
   2. Barkhof F,
   3. Desmet A

   . The effect of oral temsirolimus on new magnetic resonance imaging scan lesions, brain atrophy, and the number of relapses in multiple sclerosis: results from a randomised, controlled clinical trial. J Neurol 2005;252(suppl 2):46 (abstract 158)

   CrossRef
6. 6.↵
   1. Miller DH,
   2. Albert PS,
   3. Barkhof F,
   4. et al

   . Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis: US National MS Society Task Force. Ann Neurol 1996;39:6–16

   CrossRefPubMedWeb of Science
7. 7.↵
   1. Sormani MP,
   2. Filippi M

   . Statistical issues related to the use of MRI data in multiple sclerosis. J Neuroimaging 2007;17:56S–59S

   CrossRefPubMedWeb of Science
8. 8.↵
   1. Lindsey JK

   . Models for Repeated Measurements. 2nd ed. Oxford, UK: Oxford University Press; 1999
9. 9.↵
   1. Sormani MP,
   2. Miller DH,
   3. Comi G,
   4. et al

   . Clinical trials of multiple sclerosis monitored with enhanced MRI: new sample size calculations based on large data sets. J Neurol Neurosurg Psychiatry 2001;70:494–99

   Abstract/FREE Full Text
10. 10.↵
    1. Sormani MP,
    2. Bruzzi P,
    3. Miller DH,
    4. et al

    . Modelling MRI enhancing lesion counts in multiple sclerosis using a negative binomial model: implications for clinical trials. J Neurol Sci 1999;163:74–80

    CrossRefPubMedWeb of Science
11. 11.↵
    1. Comi G,
    2. Filippi M,
    3. Wolinsky JS

    . European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging–measured disease activity and burden in patients with relapsing multiple sclerosis. Ann Neurol 2001;49:290–97

    CrossRefPubMedWeb of Science
12. 12.↵
    1. Miller DH,
    2. Soon D,
    3. Fernando KT,
    4. et al

    . MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology 2007;68:1390–401

    Abstract/FREE Full Text
13. 13.↵
    1. Kappos L,
    2. Antel J,
    3. Comi G,
    4. et al

    . Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 2006;355:1124–40

    CrossRefPubMedWeb of Science
14. 14.↵
    1. van den Elskamp IJ,
    2. Lembcke J,
    3. Dattola V,
    4. et al

    . Persistent T1 hypointensity as an MRI marker for treatment efficacy in multiple sclerosis. Mult Scler 2008;14:764–69

    Abstract/FREE Full Text
15. 15.↵
    1. Li N,
    2. Elashoff DA,
    3. Robbins WA,
    4. et al

    . A hierarchical zero-inflated log-normal model for skewed responses. Stat Methods Med Res 2011;20:175–89

    Abstract/FREE Full Text
16. 16.↵
    1. Dunn PK

    . Occurrence quantity of precipitation can be modeled simultaneously. Int J Climatology 2004;24:1231–39

    CrossRef
17. 17.↵
    1. Shono H

    . Application of the Tweedie distribution to zero-catch data in CPUE analysis. Fisheries Research 2008;93:154–62

    CrossRefWeb of Science